Pharnext to Present at 7th Annual CEC Capital Summit
September 13 2017 - 10:45AM
Business Wire
Regulatory News:
Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA),
a biopharmaceutical company pioneering a new approach to the
development of innovative drugs based on the combination and
repositioning of known drugs, today announced that company
management will present a corporate overview at the 7th Annual CEC
Capital Summit.
The presentation will take place as follows:
- Date: Wednesday, September 20th,
2017
- Time: 2:50 pm PDT (11:50 pm
CEST)
- Venue: Montage Beverly Hills in
Beverly Hills, California
If you are interested in meeting the Pharnext management team
during this event, please send an email to Matthew Shinseki at
matthew@sternir.com.
About PharnextPharnext is an advanced clinical-stage
biopharmaceutical company founded by renowned scientists and
entrepreneurs including Professor Daniel Cohen, a pioneer in modern
genomics. Pharnext has two lead products in clinical development.
PXT3003 is currently in an international Phase 3 trial for the
treatment of Charcot-Marie-Tooth disease type 1A and benefits from
orphan drug status in Europe and the United States. PXT864 has
generated positive Phase 2 results in Alzheimer’s disease. Pharnext
is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The
Company identifies and develops synergic combinations of
repositioned drugs at new optimal lower doses. These PLEODRUG™
offer several key advantages: efficacy, safety and intellectual
property including several product or composition of matter patents
already granted. The Company is supported by a world-class
scientific team.
The company Pharnext is listed on Euronext Growth Stock Exchange
in Paris (ISIN code: FR00111911287).For more information, visit
www.pharnext.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170913005931/en/
PharnextXavier Paoli, +33 (0)1 41 09 22 30Chief
Commercial Officercontact@pharnext.comorInvestor Relations
(Europe)MC Services AGAnne Hennecke, +49 211 529252
22anne.hennecke@mc-services.euorMedia Relations
(Europe)ALIZE RPCaroline CarmagnolMargaux Pronost+33 (0)1 44 54
36 64pharnext@alizerp.comorInvestor Relations (U.S.)Stern
Investor Relations, Inc.Matthew Shinseki, +1
212-362-1200matthew@sternir.comorMedia Relations (U.S.)Russo
PartnersTony RussoScott
Santiamotony.russo@russopartnersllc.comscott.santiamo@russopartnersllc.com+1
212-845-4251+1 718-344-5843orFinancial Communication
(France)New CAPEmmanuel Huynh, +33 (0)1 44 71 20
40pharnext@newcap.eu
Pharnext (EU:ALPHA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pharnext (EU:ALPHA)
Historical Stock Chart
From Apr 2023 to Apr 2024